Ubiquitin specific peptidase 18 (USP18) is an enzyme in humans encoded by the USP18 gene. It belongs to the ubiquitin-specific protease family and specifically cleaves the ubiquitin-like modifier ISG15 from substrate proteins—a process called deISGylation. In addition to its isopeptidase activity, USP18 serves as a key negative regulator of type I interferon receptor signaling by binding IFNAR2 and disrupting JAK-STAT pathway activation. USP18 functions as a post-translational modifier and a critical immune checkpoint, controlling inflammation, antiviral responses, and cell fate. Its deregulation contributes to diverse pathologies including autoinflammatory syndromes, several cancers, infectious diseases, and metabolic disorders. Loss-of-function mutations cause severe interferonopathies, while gain-of-function or increased expression facilitate viral infection and tumor survival.
Other names
UBP43ISG15 isopeptidase
02
Mechanism of action
Drugs targeting USP18 would likely act by inhibiting its isopeptidase activity (preventing deISGylation), modulating its ability to negatively regulate interferon signaling (e.g. disruption of IFNAR2 binding), or affecting its stability/expression in disease contexts.
03
Biological functions
Negative regulation of type I interferon signalingDeISGylation (removal of ISG15 from substrate proteins)Regulation of immune responseRegulation of cell cycle, apoptosis, and cell proliferationRegulation of antiviral defense
04
Disease associations
Cancer (regulates tumor growth and chemoresistance)Autoimmune diseases (involvement in pseudo-TORCH syndrome, regulatory role in inflammation)Infection (modulates viral replication including HIV, hepatitis B, influenza)Metabolic disease (roles in lipid metabolism, diabetes)Other: Central nervous system homeostasis, neurologic inflammatory syndromes
05
Safety considerations
Suppression of USP18 leads to increased interferon responses and risk of life-threatening autoinflammatory diseaseOveractivation is associated with immune dysfunction, cancer progression, and chemoresistanceTherapeutic modulation may risk unintended immune/hormonal disturbances or exacerbate autoimmune reactions
06
Interacting drugs
Information on specific drugs directly targeting USP18 is currently limited. However, its role as a negative regulator of interferon signaling has led to interest in small molecules and biologicals that may modulate its function for cancer or autoimmune/viral diseases.
07
Biomarkers
Mutations, expression levels, or functional activity of USP18 are proposed biomarkers for interferonopathies (e.g., pseudo-TORCH syndrome)USP18 expression may also serve as a marker for inflammation, viral susceptibility, or tumor progression
Beyond the preview
Go deeper on Ubiquitin specific peptidase 18 (USP18).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ubiquitin specific peptidase 18 (USP18).